Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim animal health france scs 29 avenue tony garnier 69007 lyon francija izdelovalec -

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceva santé animale 10 avenue de la ballastière 33500 libourne francija proizvajalec odgovoren za sproščanje serij: ceva santé animale 10 -

Slovenja - Sloven - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

virbac 1 ere avenue 2065m lid 06516 carros francija 8 -

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

merck europe b.v. - avelumab - neuroendokrine tumorje - druga zdravila z delovanjem na novotvorbe agenti, monoklonalna protitelesa - zdravilo bavencio je indicirano za samostojno zdravljenje odraslih bolnikov z metastatskim karcinomom merkelove celice (mcc). bavencio v kombinaciji z axitinib je določen za prvo linijo za zdravljenje odraslih bolnikov z napredovalim karcinomom ledvičnih (rkc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastična sredstva - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatične neoplazme - endokrini terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklidno slikanje - terapevtski radiofarmacevtiki - endolucinbeta je predhodnik radiofarmacevtskega sredstva in ni namenjen neposredni uporabi pri bolnikih. je namenjena le za radioaktivno označevanje prevoznika molekul, ki so bili posebej razviti in dovoljenje za radioaktivno označevanje s kloridom lutecij (177lu).

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - radionuklidno slikanje - terapevtski radiofarmacevtiki - lumark je radiofarmacevtski predhodnik. niso namenjeni za neposredno uporabo pri bolnikih. to zdravilo je treba uporabiti le za radioaktivno označevanje nosilnih molekul, ki so bile posebej razvite in odobrene za radioaktivno označevanje s tem radionuklidom.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - imunski sera in imunoglobulini, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Sloven - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidno slikanje - terapevtski radiofarmacevtiki - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.